Upland Clinical Research

1. Chiesi USA, Inc. $274,723 22 payments
2. Bausch Health US, LLC $102,465 48 payments
3. Allergan Inc. $83,214 21 payments
4. VIVUS, Inc. $43,724 2 payments
5. Pfizer Inc. $10,000 1 payment
6. Akebia Therapeutics Inc $6,627 5 payments
7. Merck Sharp & Dohme Corporation $2,930 2 payments

1. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $189,168 14 payments
2. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis $91,865 47 payments
3. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $85,555 8 payments
4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $79,924 18 payments
5. A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject $43,724 2 payments
6. Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) $10,600 1 payment
7. A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study to Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 $10,000 1 payment
8. Akb-6548-Ci-0015 $5,997 3 payments
9. A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy $2,930 2 payments
10. 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $1,739 1 payment

1. Other $43,724 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.